These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35548241)

  • 1. Sulfur(vi) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure-activity relationship studies.
    You Y; Kim HS; Park JW; Keum G; Jang SK; Kim BM
    RSC Adv; 2018 Sep; 8(55):31803-31821. PubMed ID: 35548241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New potent biaryl sulfate-based hepatitis C virus inhibitors.
    You Y; Kim HS; Bae IH; Lee SG; Jee MH; Keum G; Jang SK; Kim BM
    Eur J Med Chem; 2017 Jan; 125():87-100. PubMed ID: 27657807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors.
    Hamdy J; Emadeldin N; Hamed MM; Frakolaki E; Katsamakas S; Vassilaki N; Zoidis G; Hirsch AKH; Abdel-Halim M; Abadi AH
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier.
    Abdallah M; Hamed MM; Frakolaki E; Katsamakas S; Vassilaki N; Bartenschlager R; Zoidis G; Hirsch AKH; Abdel-Halim M; Abadi AH
    Eur J Med Chem; 2022 Feb; 229():114034. PubMed ID: 34959173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symmetric Anti-HCV Agents: Synthesis, Antiviral Properties, and Conformational Aspects of Core Scaffolds.
    Leila ARS; Mousa MHA; Frakolaki E; Vassilaki N; Bartenschlager R; Zoidis G; Abdel-Halim M; Abadi AH
    ACS Omega; 2019 Jul; 4(7):11440-11454. PubMed ID: 31460249
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Synthesis of Novel Symmetric Fluorene-2,7-Diamine Derivatives as Potent Hepatitis C Virus Inhibitors.
    Mousa MHA; Ahmed NS; Schwedtmann K; Frakolaki E; Vassilaki N; Zoidis G; Weigand JJ; Abadi AH
    Pharmaceuticals (Basel); 2021 Mar; 14(4):. PubMed ID: 33806139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.
    Nakamura H; Fujioka S; Terui T; Okuda S; Kondo K; Tamatani Y; Akagi Y; Komoda Y; Kinoshita W; Ito S; Maeda K; Ukaji Y; Inaba T
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127361. PubMed ID: 32738974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
    Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
    Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
    Wang C; Jia L; O'Boyle DR; Sun JH; Rigat K; Valera L; Nower P; Huang X; Kienzle B; Roberts S; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5155-63. PubMed ID: 24936600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism.
    Tsai YH; Kuang WF; Lu TY; Kao JH; Lai MY; Liu CJ; Chen PJ; Hwang LH
    J Hepatol; 2008 Dec; 49(6):899-907. PubMed ID: 18842320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.
    Nguyen D; Smith D; Vaughan-Jackson A; Magri A; ; Barnes E; Simmonds P
    J Hepatol; 2020 Oct; 73(4):794-799. PubMed ID: 32470499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6.
    Dvory-Sobol H; Han B; Lu J; Yu M; Beran RK; Cheng G; Martin R; Svarovskaia E; Mo H
    J Viral Hepat; 2019 Aug; 26(8):991-1001. PubMed ID: 31009123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
    El-Shamy A; Shoji I; Kim SR; Ide Y; Imoto S; Deng L; Yoon S; Fujisawa T; Tani S; Yano Y; Seo Y; Azuma T; Hotta H
    PLoS One; 2012; 7(2):e30513. PubMed ID: 22319571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.
    Shi N; Hiraga N; Imamura M; Hayes CN; Zhang Y; Kosaka K; Okazaki A; Murakami E; Tsuge M; Abe H; Aikata H; Takahashi S; Ochi H; Tateno-Mukaidani C; Yoshizato K; Matsui H; Kanai A; Inaba T; McPhee F; Gao M; Chayama K
    Gut; 2013 Jul; 62(7):1055-61. PubMed ID: 23322441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NS5A-ISGylation via Lysine 26 Has a Critical Role for Efficient Propagation of Hepatitis C Virus Genotype 2a.
    Bawono RG; Abe T; Shibata Y; Matsui C; Deng L; Shoji I
    Kobe J Med Sci; 2021 Sep; 67(2):E38-E47. PubMed ID: 34795154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
    Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
    Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation of nonstructural 5A protein of hepatitis C virus: HCV group-specific hyperphosphorylation.
    Hirota M; Satoh S; Asabe S; Kohara M; Tsukiyama-Kohara K; Kato N; Hijikata M; Shimotohno K
    Virology; 1999 Apr; 257(1):130-7. PubMed ID: 10208927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.